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The plasma membrane calcium ATPase 4 signalling
in cardiac ﬁbroblasts mediates cardiomyocyte
hypertrophy
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The heart responds to pathological overload through myocyte hypertrophy. Here we show
that this response is regulated by cardiac ﬁbroblasts via a paracrine mechanism involving
plasma membrane calcium ATPase 4 (PMCA4). Pmca4 deletion in mice, both systemically
and speciﬁcally in ﬁbroblasts, reduces the hypertrophic response to pressure overload;
however, knocking out Pmca4 speciﬁcally in cardiomyocytes does not produce this effect.
Mechanistically, cardiac ﬁbroblasts lacking PMCA4 produce higher levels of secreted frizzled
related protein 2 (sFRP2), which inhibits the hypertrophic response in neighbouring cardio-
myocytes. Furthermore, we show that treatment with the PMCA4 inhibitor aurintricarboxylic
acid (ATA) inhibits and reverses cardiac hypertrophy induced by pressure overload in mice.
Our results reveal that PMCA4 regulates the development of cardiac hypertrophy and
provide proof of principle for a therapeutic approach to treat this condition.
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C
ardiac overload due to high blood pressure, myocardial
infarction, aortic stenosis and myoﬁlament or cytoskeletal
mutations leads to pathological hypertrophy and
eventually heart failure1–3. Controlling hypertrophic growth is
important, as it signiﬁcantly reduces the risk of developing heart
failure and sudden death4. Several treatment modalities are
commonly used to control the extra-cardiac factors that may
contribute to hypertrophic growth, notably blood pressure5;
however, no treatment has directly targeted the intra-cardiac
factors. Therefore, the investigation of the intra-cardiac
mechanisms governing hypertrophic growth is pivotal for
developing novel pathophysiologial and therapeutic concepts.
Cardiac ﬁbroblasts have recently emerged as one of the main
factors in the regulation of various pathological processes in the
heart. Cardiac ﬁbroblasts play key roles in maintaining
extracellular matrix homeostasis (reviewed in ref. 6). These cells
are commonly understood to be heavily involved in the
development of myocardial ﬁbrosis through cell proliferation
and secretion of extracellular matrix. However, recent knowledge
suggests that cardiac ﬁbroblasts are actively involved in the
regulation of a number of signalling pathways in the heart,
including those implicated in cardiac hypertrophy and
remodelling6. These cells interact with cardiomyocytes via
paracrine mechanisms and/or direct cell–cell interactions7.
Examples of factors secreted by cardiac ﬁbroblasts that may
mediate cardiomyocyte hypertrophy include growth factors (for
example, insulin-like growth factor 1 (IGF1))8 and microRNAs9.
Calcium is an important signal transducer and is essential in
the regulation of key cellular processes such as growth, survival
and gene expression10. Although regulation of the calcium signals
in cardiomyocytes is well studied, the calcium signalling
mechanism in cardiac ﬁbroblasts is relatively unknown. A
recent study has indicated that regulation of intracellular
calcium might inﬂuence cardiac ﬁbroblasts proliferation rate
and hence the development of ﬁbrosis11; however, it is not known
whether intracellular calcium in ﬁbroblasts mediates cardiac
hypertrophy.
Here we show that the plasma membrane calcium ATPase
isoform 4 (PMCA4) regulates the calcium signal in cardiac
ﬁbroblasts, which is important in the regulation of cardiac
hypertrophy. Genetic ablation and pharmacological inhibition of
PMCA4 enhances the production of secreted frizzled related
protein 2 (sFRP2) by cardiac ﬁbroblasts. sFRP2 is a potent
inhibitor of the Wnt pathway and has been described as having
potent protective effects against myocardial injury12. We also
show that targeting PMCA4 by a novel inhibitor is beneﬁcial to
the progression of cardiac hypertrophy probably through
potentiation of sFRP2 production.
Results
sFRP2 expression is elevated in PMCA4 / cardiac ﬁbroblasts.
We ﬁrst studied whether genetic ablation of Pmca4 in cardiac
ﬁbroblasts modiﬁed intracellular calcium. PMCA4 was expressed
in mouse adult cardiac ﬁbroblasts (ACFs) and its expression
was signiﬁcantly reduced in cardiac ﬁbroblasts isolated from
PMCA4 / mice as detected by immunoﬂuorescence, quanti-
tative reverse transcriptase–PCR (qRT–PCR) and western blot
analyses (Fig. 1a–c). We examined basal intracellular calcium in
these cells using the calcium sensitive dye ﬂuo-3 and found that it
was 25% higher in PMCA4 / ﬁbroblasts compared with wild
type (WT; Fig. 1d). This ﬁnding suggests that PMCA4 plays a key
role in maintaining physiological calcium levels in cardiac
ﬁbroblasts.
As calcium mediates multiple signalling pathways and
gene expression, we investigated the transcription proﬁle in
PMCA4 / ﬁbroblasts. Using an Affymetrix microarray
GeneChip technology, we ﬁrst examined the messenger RNA
expression proﬁle of PMCA4 / ﬁbroblasts. Interestingly, we
found that several genes involved in regulating Wnt signalling
were elevated in PMCA4 / ﬁbroblasts, such as sFRP2 and
IGF-binding protein (IGFBP) 4 and 5 (Supplementary Fig. 1A).
qRT–PCR and western blots analyses conﬁrmed that sFRP2
mRNA and protein were signiﬁcantly and consistently elevated
in PMCA4 / cardiac ﬁbroblasts (Fig. 1e–g). In addition,
qRT–PCR analysis showed that IGFBP4 and IGFBP5 were also
elevated in PMCA4 / ﬁbroblasts (Supplementary Fig. 1B,C).
However, in this study we focused on sFRP2, as it is known
that this molecule plays an essential role in mediating cardiac
remodelling12,13.
sFRP2 expression is induced by the transcription factor Pax2
(ref. 14). We therefore analysed Pax2 expression and found it to
be signiﬁcantly elevated in PMCA4 / cardiac ﬁbroblasts
(Fig. 1h). To further investigate the mechanism by which PMCA4
regulates sFRP2 expression, we then focused on nuclear factor-kB
(NF-kB) signalling because: (i) NF-kB regulates Pax2
expression15 and (ii) PMCA4 has been demonstrated to be an
upstream regulator of NF-kB16. Using an adenoviral-mediated
NF-kB-luciferase reporter construct, we detected signiﬁcantly
higher NF-kB activity in PMCA4 / ﬁbroblasts (Fig. 1i). This
increase might be due to the elevated intracellular calcium in
PMCA4 / ﬁbroblasts, because NF-kB activity has been
associated with intracellular calcium levels17. To further
conﬁrm if NF-kB signalling regulates sFRP2 expression, we
treated ﬁbroblasts with the NF-kB inhibitor BAY11–7082
(10 mM). As shown in Fig. 1j, the level of sFRP2 expression in
PMCA4 / ﬁbroblasts was signiﬁcantly reduced following
treatment with BAY11–7082. Together, our data suggested that
signalling via NF-kB and Pax2 pathways may be responsible for
the raised sFRP2 expression in these cells.
PMCA4 / ﬁbroblast conditioned medium attenuates
hypertrophy. sFRP2 is a potent inhibitor of Wnt signalling,
which plays key roles in mediating cardiac growth and patholo-
gical hypertrophy18. Therefore, we hypothesized that higher
sFRP2 production by PMCA4 / cardiac ﬁbroblasts may
protect against cardiomyocyte hypertrophy via a paracrine
mechanism. To test this hypothesis, we performed in vitro
experiments using isolated neonatal rat cardiomyocytes
(NRCMs). After 2 days of culture in normal medium, we
treated NRCMs with conditioned medium from either WT or
PMCA4 / ACFs. We then induced cellular hypertrophy by
stimulating cells with phenylephrine (30 mM for 72 h) and
measured cell size, and found that NRCMs showed a
signiﬁcantly less hypertrophic response when treated with
conditioned medium from PMCA4 / ﬁbroblasts compared
with WT ﬁbroblasts (Fig. 2a,b). Analysis of the levels of atrial
natriuretic peptide (ANP) and brain natriuretic peptide (BNP)
expression also supported this ﬁnding (Supplementary Fig. 2A,B).
This data indicated that PMCA4 / ﬁbroblasts might secrete a
factor that represses hypertrophy. To test whether sFRP2 was the
important factor, we conducted rescue experiments by inhibiting
sFRP2 activity with an anti-sFRP2 antibody added to the
conditioned medium. Treating the cells with anti-sFRP2
abolished the anti-hypertrophic effect of the conditioned
medium from PMCA4 / ﬁbroblasts (Fig. 2a,b). Furthermore,
we performed enzyle-linked immunosorbent assay analysis of the
conditioned medium, which showed that the level of sFRP2 was
signiﬁcantly higher in conditioned medium from PMCA4 /
ﬁbroblasts compared with WT ﬁbroblasts (Fig. 2c). To examine
whether Wnt signalling was affected, we generated adenovirus
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carrying the Wnt-luciferase reporter construct19. Using this
construct, we showed that in cells treated with conditioned
medium from PMCA4 / ﬁbroblasts, the phenylephrine-
induced Wnt signalling was signiﬁcantly lower compared with
cells in conditioned medium from WT ﬁbroblasts (Fig. 2d).
Consistently, treatment with anti-sFRP2 antibody abolished the
difference in Wnt signal activation (Fig. 2d). These results
demonstrated that PMCA4 / ﬁbroblasts protect against
phenylephrine-induced cardiomyocyte hypertrophy, possibly by
secreting sFRP2. We also tested the anti-hypertrophic effect
of PMCA4 / ﬁbroblast conditioned medium when used to
culture adult rat cardiomyocytes. Consistent results were obtained
from experiments using isolated adult rat cardiomyocytes as
shown in Supplementary Fig. 2C,D.
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Figure 1 | Pmca4 gene ablation increased sFRP2 expression in ACFs. (a) Immunoﬂuorescence analysis of ACFs isolated from WTand PMCA4 / mice.
Cells were stained with anti-DDR2 (ﬁbroblasts marker) and anti-PMCA4 antibodies (scale bars, 25mm). (b) qRT–PCR analysis showing a signiﬁcant
reduction in Pmca4 level in ACFs of PMCA4 / mice (n¼4; *Po0.05). (c) Western blotting to detect PMCA4 protein level in ACFs and quantiﬁcation of
band density showing signiﬁcant reduction of PMCA4 expression in PMCA4 / cardiac ﬁbroblasts (n¼4; *Po0.05). (d) Analysis of basal intracellular
calcium showed signiﬁcantly elevated intracellular calcium level in PMCA4 / cardiac ﬁbroblasts (n¼4; *Po0.05). (e) Real-time RT–PCR and
(f) western blot analysis, to examine sFRP2 expression in cardiac ﬁbroblasts. (g) Quantiﬁcation of band density supported the qRT–PCR analysis, showing
signiﬁcantly increased sFRP2 expression in PMCA4 / ﬁbroblasts (n¼ 5; *Po0.05. (h) Expression of Pax2 was also elevated in PMCA4 / ﬁbroblasts
(n¼4; *Po0.05). (i) Using adenovirus-mediated NF-kB luciferase reporter construct, we detected a higher level of NF-kB activity in ﬁbroblasts lacking
PMCA4 (n¼4; *Po0.05). (j) Treatment with NF-kB inhibitor (BAY11–7082) at 10mM for 24 h remarkably reduced sFRP2 mRNA level in PMCA4 /
ﬁbroblasts as detected by qRT–PCR (n¼4; *Po0.05). Student’s t-test was used in all statistical tests above. All error bars represent the s.e.m.
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TAC-induced hypertrophy is attenuated in PMCA4 / mice.
To investigate the anti-hypertrophic effect of ablating the Pmca4
gene in vivo, we analysed our PMCA4 global knockout (KO) mice
(PMCA4 / mice)20. In PMCA4 / hearts, PMCA4 was
completely ablated as we previously described21. We found that
sFRP2 expression was increased in the hearts of PMCA4 /
mice (Fig. 3a). We then subjected these mice to transverse aortic
constriction (TAC) for 5 weeks, to induce cardiac pressure
overload. Systemic deletion of PMCA4 attenuated pathological
hypertrophy in response to pressure overload as shown by heart
weight/tibia length (HW/TL) ratio, cardiomyocyte cell surface
area and echocardiography assessments (Fig. 3b–e and
Supplementary Table 1). In these mice, the hypertrophic
marker ANP was also lower (Supplementary Fig. 3A). However,
we did not observe changes in cardiac contractility in response to
TAC, as indicated by the haemodynamic parameters dP/dtmax
and dP/dtmin (Supplementary Fig. 3B,C).
To examine activation of the Wnt pathway in this model,
we measured the level of active (non-phosphorylated) b-catenin.
After TAC, active b-catenin was signiﬁcantly lower in PMCA4 /–
TAC mice (Fig. 3f,g). Consistent with this ﬁnding, TCF4,
a b-catenin target gene, was signiﬁcantly reduced in PMCA4 /–
TAC compared with WT–TAC mice, as measured by qRT–PCR
(Supplementary Fig. 3D). These results suggested that the
Wnt/b-catenin pathway was downregulated after TAC in
PMCA4 / mice compared with WT.
Next, we analysed how PMCA4 / mice responded to
exercise-induced cardiac hypertrophy by subjecting them
to swimming for 4 weeks. In contrast to the TAC model,
the hypertrophic response to swimming exercise was
unaltered (Supplementary Fig. 3E) suggesting that PMCA4
speciﬁcally regulates pathological but not physiological cardiac
hypertrophy.
To analyse the extent of cardiac ﬁbrosis, we stained heart
tissue sections with Masson’s trichrome staining. As shown in
Supplementary Fig. 3F,G, we did not ﬁnd any signiﬁcant
difference in the level of ﬁbrosis between PMCA4 / mice
and WT controls.
Pmca4 ablation protects against long-term pressure overload.
Although our 5 weeks TAC model was sufﬁcient to induce
hypertrophy, we did not observe any signiﬁcant effect on cardiac
function as indicated by haemodynamic data. Therefore, we
performed a more severe model by inducing long-term pressure
overload for 12 weeks in PMCA4 / mice. With this TAC
model, we found that WT mice had a dramatically reduced
survival rate (40% survival after 12 weeks of TAC), while all of the
PMCA4 / mice survived until 12 weeks following TAC
(Fig. 3h). When we assessed cardiac function in surviving animals
at 12 weeks after TAC, we found that PMCA4 / mice had
signiﬁcantly better contractility as indicated by dP/dtmax and
dP/dtmin values (Supplementary Fig. 4A,B). These data showed
that Pmca4 gene deletion protected against the development
of contractile dysfunction and improved the survival after
long-term TAC.
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Figure 2 | PMCA4 / ﬁbroblast conditioned medium exerts an anti-hypertrophic effect. (a) Representative images of NRCMs cultured in conditioned
medium of either WT or PMCA4 / cardiac ﬁbroblasts. NRCMs were treated with phenylephrine (PE), 30mM or PE with anti-sFRP2 antibody
(0.2mgml 1) for 72 h. Cells were then stained with a-actinin antibody, to speciﬁcally visualize cardiomyocytes. Scale bar, 25mm. (b) Measurement of cell
surface area indicated that treatment with PMCA4 / ﬁbroblasts conditioned medium (KO) signiﬁcantly reduced PE-induced hypertrophy (results were
from three independent experiments conducted in triplicate; a minimum of 100 cells were measured per replicate, *Po0.05, one-way analysis of variance
(ANOVA) followed by post-hoc multiple comparison). Addition of anti-sFRP2 antibody abolished the anti-hypertrophic effect of PMCA4 / conditioned
medium. (c) ELISA analysis showed a signiﬁcantly higher sFRP2 level in PMCA4 / conditioned medium (n¼4 in each group; *Po0.05, Student’s t-test).
(d) Using an adenovirus expressing the TCF/LEF-luciferase construct, we detected activation of the Wnt/b-catenin pathway. Consistent with this
observation, conditioned medium from PMCA4 / ﬁbroblasts inhibited PE-induced Wnt/b-catenin activation, which was reversed by treatment with
anti-sFRP2 antibody (n¼ 3 independent experiments; *Po0.05, one-way ANOVA followed by post-hoc multiple comparison). All error bars represent
the s.e.m.
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sFRP2 contributes to attenuated hypertrophy in PMCA4 /
mice. To investigate whether the protection against TAC-induced
hypertrophy in PMCA4 / mice was due to the expression of
sFRP2, we subjected PMCA4 / mice to TAC surgery and then
treated them with anti-sFRP2 antibody (200 mg per kg body
weight per day, intraperitoneally (i.p.)) or normal goat IgG at a
similar dose as control. Immunoprecipitation analysis showed
that injection with anti-sFRP2 antibody increased the interaction
between Wnt and its receptor, Frizzled, in the heart
(Supplementary Fig. 5A). This data indicated that anti-sFRP2
antibody treatment successfully blocked sFRP2 activity in vivo.
Furthermore, we found that the hypertrophic response to TAC
was restored in PMCA4 / mice treated with anti-sFRP2 anti-
body as indicated by analysis of left ventricular mass/TL ratio,
cardiomyocyte cross-sectional area and BNP expression
(Supplementary Fig. 5B–F). In contrast, PMCA4 / mice
treated with control IgG displayed an attenuated hypertrophic
response. The level of active b-catenin was remarkably increased
following anti-sFRP2 treatment in TAC-treated mice,
but in sham-treated animals we observed only slight (B12%)
elevation of active b-catenin level after anti-sFRP2 treatment
(Supplementary Fig. 5G,H). This might be due to the fact that
the Wnt pathway is basally inactive in the adult heart and
re-activated in pathological conditions including pressure
overload18. Overall, our data suggests that the anti-hypertrophic
effect of PMCA4 ablation in mice was at least in part due to
sFRP2 expression.
Hypertrophy unaltered by Pmca4 ablation in cardiomyocytes.
To investigate the effects of PMCA4 cell-speciﬁc ablation in the
heart, we generated conditional KO models. We generated mice
carrying loxP sequences ﬂanking exons 2 and 3 of the Pmca4
gene, which contain the start codon (Supplementary Fig. 6).
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Figure 3 | Systemic deletion of Pmca4 attenuated the hypertrophic response to TAC. (a) sFRP2 level was detected in heart tissues using qRT–PCR (WT,
n¼4; PMCA4 / , n¼ 3; *Po0.05, Student’s t-test). (b) Representative image of hearts from WT and PMCA4 / mice following TAC (5 weeks) or
sham operation (scale bar, 5mm). (c) Measurement of HW/TL ratio showed signiﬁcant reduction of the hypertrophic response in PMCA4 / mice
(n¼ 10 in each group; *Po0.05, one-way analysis of variance (ANOVA) followed by post-hoc multiple comparison). (d) Representative heart tissue
sections stained with haematoxylin and eosin, and (e) measurement of cardiomyocyte cross-sectional area showed smaller cardiomyocyte size in
PMCA4 / mice after TAC (scale bars, 50mm,*Po0.05, one-way ANOVA followed by post-hoc multiple comparison). (f) Western blot analysis of active
b-catenin and (g) quantiﬁcation of band density level indicated a higher level of b-catenin activation in PMCA4 / mice after TAC (n¼4 in each group;
*Po0.05, one-way ANOVA followed by post-hoc multiple comparison). (h) When stimulated with long-term (12 weeks) TAC, more PMCA4 / mice
survived than WT. All of the sham-treated animals survived at 12 weeks following procedure (WT, n¼ 7; PMCA4 / n¼ 5 at the beginning of the
experiments). All error bars represent the s.e.m.
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We crossed these mice with aMHC-Cre transgenic mice to
establish PMCA4 cardiomyocyte-speciﬁc KO mice (PMCA4cko).
Expression analyses conﬁrmed the speciﬁc ablation of PMCA4 in
the cardiomyocytes, whereas the cardiac ﬁbroblasts retained
PMCA4 expression (Fig. 4a–e). We then subjected these mice to
TAC for 5 weeks and used Pmca4 ﬂoxed mice (PMCA4ﬂox/ﬂox) as
controls. After 5 weeks of pressure overload, PMCA4cko did not
display differences in the hypertrophic response, as indicated
by HW/TL ratio, cardiomyocyte cross-sectional area and
echocardiographic analysis (Fig. 4f–i and Supplementary
Table 2). In addition, the level of ANP expression was not
different between PMCA4cko and PMCA4ﬂox/ﬂox mice
(Supplementary Fig. 7A). By analysing cardiac haemodynamics
(dP/dtmax and dP/dtmin), we also found that there was no dif-
ference in cardiac contractile function between PMCA4ﬂox/ﬂox
and PMCA4cko mice after TAC (Supplementary Fig. 7B,C).
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the heart of PMCA4cko mice. (b) Western blot analysis showing PMCA4 expression in several organs and in isolated cardiomyocytes and cardiac
ﬁbroblasts. (c) Quantiﬁcation of band density (relative to expression in control mice) showed that expression of PMCA4 was ablated only in
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showed no difference in the level of active b-catenin between PMCA4cko and controls (n¼ 5 per group), NS, not signiﬁcant. All error bars represent
the s.e.m.
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Furthermore, active b-catenin levels and TCF4 gene expression
were not different between PMCA4cko and PMCA4ﬂox/ﬂox mice
after TAC, suggesting that Wnt/b-catenin signal activation was
unaltered (Fig. 4j,k and Supplementary Fig. 7D). Similar to the
data from PMCA4 / mice, PMCA4cko did not show any
difference in the level of ﬁbrosis compared with controls
(Supplementary Fig. 7E,F). Together, this data conﬁrmed that the
protective effect of PMCA4 ablation was not through signalling in
cardiomyocytes.
Pmca4 deletion in ﬁbroblasts reduces hypertrophy after TAC.
Next, we generated a PMCA4 ﬁbroblasts-speciﬁc KO (PMCA4fko)
by crossing PMCA4ﬂox/ﬂox mice with Postn-Cre transgenic mice.
These mice express Cre recombinase under the control of the
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Figure 5 | Fibroblast-speciﬁc Pmca4 ablation reduced TAC-induced hypertrophy. (a) Image of PCR analysis to detect the deleted Pmca4 allele in
PMCA4fko mice. (b) Western blotting showing the expression of PMCA4 in several different organs and in isolated cardiomyocytes and cardiac ﬁbroblasts.
(c) Quantiﬁcation of band density (relative to expression in control mice) showed that expression of PMCA4 was ablated only in cardiac ﬁbroblasts of
PMCA4fko mice (n¼ 3; *Po0.05, Student’s t-test). (d) Adult cardiomyocytes and (e) cardiac ﬁbroblasts were stained with anti-PMCA4 (green) and
phalloidin or anti-DDR2 (red). Expression of PMCA4 was ablated in isolated ACFs but not in cardiomyocytes of PMCA4fko mice (scale bars, 25mm).
(f) Image of hearts from PMCA4fko and control littermates after TAC for 5 weeks. (g) HW/TL ratio analysis showed signiﬁcantly reduced hypertrophy in
PMCA4fko mice following TAC (control sham, n¼4; control TAC, n¼ 5; PMCA4fko sham, n¼4; PMCA4fko TAC, n¼4, *Po0.05, one-way analysis of
variance (ANOVA)). (h) Examples of histological sections stained with haematoxylin and eosin, and (i) calculation of cross-sectional cardiomyocyte area
indicated a signiﬁcantly reduced hypertrophy in PMCA4fko mice (scale bars, 50mm, control sham, n¼4; control TAC, n¼ 5; PMCA4fko sham, n¼4;
PMCA4fko TAC, n¼4; *Po0.05, one-way ANOVA). (j) Active b-catenin level was detected by western blotting. (k) Band density assessment suggested
a strong trend (P¼0.08) in reduced b-catenin activation in PMCA4fko following TAC (control sham, n¼4; control TAC, n¼ 5; PMCA4fko sham, n¼4;
PMCA4fko TAC, n¼4). All error bars represent the s.e.m.
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Periostin (Postn) gene promoter8,22 and have been demonstrated
to knock out genes speciﬁcally in cardiac ﬁbroblasts but not in
cardiomyocytes8,23. The deleted allele was present in DNA
isolated from the heart of PMCA4fko, although as expected, the
WT (non-deleted) allele was also present in the heart, presumably
as a consequence of DNA from cardiomyocytes (Fig. 5a). Using
western blotting and immunoﬂuorescence, we found speciﬁc
ablation of PMCA4 expression in isolated cardiac ﬁbroblasts
of PMCA4fko mice, whereas expression of PMCA4 in
cardiomyocytes remained unaltered (Fig. 5b–e). To induce
pressure-overload hypertrophy, we subjected PMCA4fko to TAC
for 5 weeks. In contrast to the data from PMCA4cko mice,
PMCA4fko exhibited a signiﬁcantly reduced hypertrophic
response, as indicated by measurement of HW/TL ratio, the
cross-sectional area of cardiomyocytes and analysis of
echocardiographic parameters (Fig. 5f–i and Supplementary
Table 3). Furthermore, qRT–PCR data showed a signiﬁcantly
reduced level of the hypertrophic marker ANP in PMCA4fko after
TAC (Supplementary Fig. 8A). However, consistent with data
from PMCA4 / mice, contractile function was unchanged in
PMCA4fko compared with control mice following TAC
(Supplementary Fig. 8B,C). By analysing Wnt/b-catenin signal
activation, we found that both active b-catenin and expression of
TCF4 were decreased in PMCA4fko mice after TAC compared
with WT (Fig. 5j,k and Supplementary Fig. 8D). However,
consistent with data obtained from PMCA4 / mice there was
no difference in the level of ﬁbrosis in PMCA4fko compared with
control mice (Supplementary Fig. 8E,F). These results clearly
supported the idea that signal modulation by PMCA4 in cardiac
ﬁbroblasts was important in mediating the anti-hypertrophic
effect.
Pharmacological PMCA4 inhibition enhances sFRP2 expression.
Data from our animal models together with observations in
isolated cardiac ﬁbroblasts prompted us to speculate that a
reduction in PMCA4 activity in cardiac ﬁbroblasts will provide a
beneﬁcial effect against pathological stimuli in the heart. By
screening a library of medically optimized drug-like molecules
we have identiﬁed aurintricarboxylic acid (ATA) as a potent
pharmacological inhibitor of PMCA4 (ref. 24). ATA has an IC50
of 150 nM for PMCA4 inhibition and only produced a minor
effect on the second isoform of PMCA expressed in the heart,
PMCA1 (ref. 24). We found that ATA inhibits PMCA4 activity
at a very low concentration (IC50¼ 150 nM) (ref. 24). However,
it is also known that at higher concentrations ATA also inhibits
other enzymes, such as nucleases (at 10–50 mM) (ref. 25), calpain
(IC50¼ 22 mM) (ref. 26) and inﬂuenza virus neuraminidase
(at 100mgml 1 or B210mM) (ref. 27). Therefore, in this study
we used a very low dose of ATA (1 mM), to ensure that its effects
are probably only due to PMCA4 inhibition.
We treated WT cardiac ﬁbroblasts with ATA at this dose for
48 h and found that it increased the basal level of calcium (Fig. 6a)
and NF-kB activity (Fig. 6b). We also found that extending this
treatment to 3 or 10 days signiﬁcantly enhanced sFRP2
expression in isolated WT cardiac ﬁbroblasts (Fig. 6c). To
examine whether ATA treatment increased cardiac sFRP2
expression in vivo, we injected WT C57Bl/6 mice with ATA
(5mg per kg body weight per day, i.p.) for 2 weeks. We found that
cardiac sFRP2 was signiﬁcantly increased in ATA-treated mice
(Fig. 6d).
ATA treatment attenuates TAC-induced hypertrophy. Next, we
tested the effects of ATA on pressure-overload hypertrophy
in vivo. We treated WT C57Bl/6 mice with ATA (5mg per kg
body weight per day) from day 3 before TAC until 2 weeks after.
ATA remarkably reduced the hypertrophic response as indicated
by decreased HW/TL ratio, cell surface area and expression of the
hypertrophic marker ANP (Fig. 7a–e). To analyse activation of
the Wnt/b-catenin pathway, we examined the levels of TCF4 gene
expression and active b-catenin in the heart, and found that
they were downregulated in TAC animals treated with ATA
(Fig. 7f–h). However, cardiac contractility was unaltered
(Supplementary Fig. 9A,B), which was consistent with the data
from our KO models.
ATA reverses established cardiac hypertrophy. We then tested
whether ATA could reverse previously established cardiac
hypertrophy (‘treatment strategy’) (Fig. 8a). Starting 1 week after
TAC, we treated C57Bl/6 mice with ATA at 5mg per kg body
weight per day. Echocardiography conﬁrmed myocardial hyper-
trophy at this stage (Supplementary Fig. 10A). Histological ana-
lysis, HW/TL ratio measurement and expression of hypertrophic
markers ANP and BNP showed that ATA treatment signiﬁcantly
reversed the hypertrophic response (Fig. 8b–f). Furthermore,
serial echocardiography analysis revealed that the reduction in left
ventricular mass/TL ratio began after ATA treatment (Fig. 8g),
suggesting that the effect was due to ATA treatment. Similar
to our other models, we did not observe changes in cardiac
contractility in this model (Supplementary Fig. 10B,C).
As an initial step to assess whether systemic treatment of ATA
(5mg per kg body weight per day for 2 weeks) produces adverse
effects in other major organs such as the liver and kidney, we
measured the level of serum alanine transaminase, aspartate
transaminase and creatinine in ATA-treated mice. As shown in
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Figure 6 | PMCA4 inhibition increased sFRP2 levels in cardiac ﬁbroblasts
and the heart. (a) ACFs isolated from WTmice were subjected to ATA
treatment (1mM for 48 h). Measurement of basal intracellular calcium using
ﬂuo-3 dye indicated a signiﬁcantly higher calcium level in ATA-treated cells
(n¼4; *Po0.05, Student’s t-test). (b) Analysis of NF-kB activity using the
NF-kB-luciferase construct showed a signiﬁcant increase in NF-kB activity
in ATA-treated cells (n¼4; *Po0.05, Student’s t-test). (c) ACFs were
treated with ATA (1mM) for 3 or 10 days. qRT–PCR analysis showed that
sFRP2 level was signiﬁcantly enhanced in ATA-treated cells (n¼4;
*Po0.05, Student’s t-test). (d) WT mice were injected with ATA
(5mg kg 1 per day for 2 weeks). sFRP2 level was detected in total heart’s
mRNA. Results showed a signiﬁcant increase in sFRP2 level (n¼6–8 in
each group; *Po0.05, Student’s t-test). All error bars represent the s.e.m.
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Supplementary Fig. 11A,B, we did not ﬁnd any difference
between ATA- and vehicle-treated mice. This suggested that the
ATA treatment was unlikely to cause toxicity in major organs
such as the liver and kidney.
ATA treatment in PMCA4 knockout mouse models. To further
conﬁrm that the anti-hypertrophic effect of ATA is due to the
inhibition of PMCA4, we performed TAC on PMCA4 global KO
mice (PMCA4 / ) and treated them with ATA. If ATA had
additional PMCA4-independent effects, the expectation would be
that it would further reduce HW, cell size and expression of
hypertrophic markers in PMCA4 / animals. Data shown in
Fig. 9a–f showed that ATA treatment did not further reduce these
parameters in the PMCA4 / mice.
We then examined whether ATA had any anti-hypertrophic
effects when PMCA4 was speciﬁcally ablated in cardiomyocytes.
As shown in Fig. 10a–f, ATA treatment reduced hypertrophy in
PMCA4cko mice as indicated by HW/TL ratio, cell size
measurement and analysis of the hypertrophic marker BNP,
suggesting that the anti-hypertrophic effect of ATA in vivo was
not via modulating PMCA4 in cardiomyocytes. To conﬁrm this
ﬁnding in vitro, we tested the effect of ATA treatment on isolated
cardiomyocytes. At 1 mM, ATA did not signiﬁcantly alter
phenylephrine-induced cardiomyocyte hypertrophy (30 mM
phenylephrine for 72 h), as indicated by cell surface area analysis
(Supplementary Fig. 12A,B).
Finally, we evaluated the effects of ATA treatment on
PMCA4fko mice. In contrast to the data obtained from PMCA4cko
mice, ATA treatment did not produce an anti-hypertrophic effect
in PMCA4fko mice as shown in Fig. 10g–l. Together, the data
provide strong support that the anti-hypertrophic effect of ATA
was due to modulation of PMCA4 in cardiac ﬁbroblasts.
Discussion
Overall, our results show that PMCA4 is a key regulator of
pathological cardiac hypertrophy that can be pharmacologically
targeted. With global and conditional KO models and an in vitro
system, we demonstrated that PMCA4 mediates a paracrine
mechanism in the heart. Inhibiting PMCA4, both genetically and
pharmacologically, elevated expression of sFRP2 in cardiac
ﬁbroblasts, which inhibited Wnt signalling in cardiomyocytes
and protected them from developing pathological hypertrophy.
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Importantly, we also showed that a novel and potent inhibitor of
PMCA4, ATA24, efﬁciently reduced pathological hypertrophy.
These data provide in vivo evidence that PMCA4 is a promising
and readily ‘druggable’ target for anti-hypertrophic therapy.
The role of cardiac ﬁbroblasts in mediating cellular signalling
in the heart is increasingly evident. Traditionally, ﬁbroblasts have
been regarded as the main regulator of extracellular matrix
composition due to their capacity in producing components
of the extracellular matrix28. However, recent knowledge has
suggested that cardiac ﬁbroblasts can mediate signal transmission
in the heart through paracrine mechanisms or cell–cell contact7.
Cardiac ﬁbroblasts secrete a number of proteins that regulate
key processes in the heart, such as the pro-hypertrophic
factor ﬁbroblast growth factor-2 (ref. 29), the cytoprotective
substance IGF1 (ref. 8), and interleukin-33, which are also
anti-hypertrophic30. Furthermore, cardiac ﬁbroblasts may also
release microRNA to the neighbouring cells, including miR21-3p,
a ﬁbroblast-derived microRNA, which modulates cardiac
hypertrophy9.
On the basis of this knowledge, we studied calcium signalling
in cardiac ﬁbroblasts, in particular those regulated by PMCA4.
This is because PMCA4 is known to be a major regulator of local
calcium signals in cardiomyocytes21,31–33, but its role in cardiac
ﬁbroblasts is relatively unknown. Our observations demonstrate
that PMCA4 regulates expression of major signalling molecules in
cardiac ﬁbroblasts. Speciﬁcally, we identiﬁed that inhibiting
PMCA4 expression/activity signiﬁcantly increased expression of
sFRP2, a potent inhibitor of the Wnt pathway. The mechanism
may be due to the increase in NF-kB activity and Pax2 expression
level. Pax2 is the major transcription factor responsible for sFRP2
expression14, whereas NF-kB regulates Pax2 expression15.
Consistent with this, we showed that Pax2 expression and
NF-kB activity were increased in PMCA4 / ﬁbroblasts.
Increased NF-kB activity might be caused by increased resting
levels of intracellular calcium in PMCA4 / ﬁbroblasts, similar
to the mechanism described previously in mdx skeletal
myotubes17.
The Wnt signalling pathway is a major regulator of cardiac
development, hypertrophy and failure; it is normally active
during embryonic development and is re-activated under
pathological conditions18. Activation of this pathway will
induce the canonical downstream pathway via b-catenin. The
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overall result is the activation of a gene programme for growth
and development18,34. Consistent with this knowledge, our
PMCA4 / mice, which express higher levels of Wnt inhibitor
sFRP2, exhibited a reduced hypertrophic response to pressure-
overload stimulus. Experiments using conditional KO models
together with analyses using a cellular model strongly indicate a
paracrine mechanism in this process. In addition, treatment with
anti-sFRP2 antibody abolishes the anti-hypertrophic effect of
PMCA4 ablation in mice providing direct in vivo evidence that
sFRP2 is a downstream effector of PMCA4-mediated signalling.
In these models we did not observe any alteration in cardiac
function following 5 weeks of TAC in both WT and KO mice.
However, we found a dramatic reduction in heart function and a
higher mortality rate in WT mice compared with PMCA4 /
mice after 12 weeks of TAC, indicating that PMCA4 ablation may
preserve cardiac contractile function and protect against the
development of heart failure in the chronic pressure overload
model.
Despite protection against pressure-overload-induced enlarge-
ment of the cardiomyocytes, we did not observe a signiﬁcant
reduction in cardiac ﬁbrosis in our global and cell-speciﬁc
PMCA4 KO strains following TAC surgery. Previous studies have
provided conﬂicting evidence regarding the role of sFRP2 in
mediating cardiac ﬁbrosis in the myocardial infarction model.
Kobayashi et al.13 showed that genetic ablation of sFRP2 reduced
the extent of cardiac ﬁbrosis following myocardial infarction,
suggesting that sFRP2 might promote the development of ﬁbrosis.
In contrast, other studies have demonstrated that injection of
recombinant sFRP2 directly into an infarcted heart resulted in
attenuated remodelling and ﬁbrosis12, indicating a protective role
for sFRP2. It is well observed that in general the extent of ﬁbrosis
following TAC is considerably less than after myocardial
infarction and, as such, this may explain why we did not see
any difference in the ﬁbrosis level in our models. It would
therefore be very interesting to evaluate the effect of PMCA4
inhibition in a model of myocardial infarction; however, these
experiments are beyond the scope of this study.
The process of generating our PMCA4 global KO mice has
been described previously20. We targeted exon 2 and part of exon
3 of the mouse Pmca4 gene using a neomycin cassette. As exon 2
contains the start codon, this strategy completely ablated PMCA4
protein from the heart, as described in our previous publication21.
Another study, described after that publication, developed a
second Pmca4-targeted mouse line, in which codons 448–474 in
exon 11 were replaced by a neomycin cassette35. This strategy
did not result in a complete KO, as the truncated Pmca4
mRNA transcript could still be detected in all tissues tested35.
Furthermore, Afroze et al.36 compared the expression of PMCA4
in both KO lines and demonstrated that PMCA4 was completely
absent from our KO mice, but not the other line. The difference
in the nature of the KO models may explain the discrepancy of
the phenotypes observed in these two lines of KO mice.
Preliminary descriptive data by Wu et al.33 suggested a
minimal (o10%) increase in the hypertrophic response to TAC
in the ‘exon 11 targeted’ PMCA4 KO line. However, further study
using this KO line is in agreement with our current data: it was
shown that cross-breeding of a hypertrophic cardiomyopathy
mouse model with this PMCA4 KO line resulted in the reduction
of hypertrophy37. In addition, our recent ﬁndings are supported
by data from two other conditional KOs, which should clarify
that any discrepancy is due to expression level as described above.
It is also important to note that PMCA4 may also have a
signalling role in the cardiomyocytes. We previously showed
that moderately overexpressing PMCA4 (B2-fold) in cardiac
myocytes reduced the b-adrenergic contractile response and
exaggerated the hypertrophic response following chronic
stimulation with isoproterenol32. In contrast, overexpressing
PMCA4 at high levels (B6-fold) in cardiomyocytes reduced
hypertrophy following TAC33. In the latter model, PMCA4
recruited calcineurin, which eventually reduced the calcineurin/
nuclear factor of activated T-cells (NFAT) signal activity33. Thus,
overexpressing PMCA4 at non-physiological levels may produce
an anchoring effect to its interacting partners, including
calcineurin. Indeed, in cardiomyocytes isolated from our
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Figure 9 | ATA had no additional effect on hypertrophy in PMCA4 / mice following TAC. (a) Image of PMCA4 / hearts at the end of experiments.
(b) Measurement of HW/TL ratio and analysis of cross-sectional cell surface area on histological sections (scale bars, 50 mm). (c,d) ATA treatment did not
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PMCA4 / mice, membrane calcineurin was reduced but total
calcineurin was unaltered (Supplementary Fig. 13). In support of
this notion, we recently showed that PMCA4 exerts an anchoring
effect on neuronal nitric oxide synthase (nNOS)21. This suggests
that the effects of PMCA4 overexpression might depend on the
level of transgene expression and might explain the phenotype
discrepancy between different transgenic lines.
Although systemic ablation of PMCA4 resulted in almost
complete attenuation of the hypertrophic response, the effect of
PMCA4 KO in ﬁbroblasts showed a signiﬁcant but not complete
attenuation of the hypertrophic response. This indicated that
PMCA4 ablation in other cell types such as endothelial and
smooth muscle cells might contribute to the modulation of
cardiac hypertrophy. Indeed, several reports have shown that
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Figure 10 | ATA inhibited cardiac hypertrophy in PMCA4cko but not PMCA4fko mice. (a) Gross morphology of the hearts from PMCA4cko mice at the end
of the experiments. (b) HW/TL ratio measurement indicated signiﬁcantly reduced hypertrophy after ATA treatment in PMCA4cko mice (sham vehicle, n¼ 5;
TAC vehicle, n¼ 6; TAC ATA, n¼ 6; *Po0.05, one-way analysis of variance (ANOVA)). (c) Representative histological sections (scale bars, 50mm) and
(d) measurement of cell surface area showed a signiﬁcant reduction of hypertrophy following ATA treatment (sham vehicle, n¼ 5; TAC vehicle, n¼ 6; TAC
ATA, n¼ 6; *Po0.05, one-way ANOVA). (e) ANP level did not differ following ATA treatment but BNP expression (f) was signiﬁcantly reduced in
PMCA4cko-TAC after ATA treatment (sham vehicle, n¼ 5; TAC vehicle, n¼ 5; TAC ATA, n¼4; *Po0.05). (g) Hearts from PMCA4fko following TAC with or
without ATA treatment. (h) Analysis of HW/TL ratio and (i,j) cross-sectional cardiomyocyte area (scale bars, 50mm) showed that ATA treatment did not
alter the hypertrophic response in PMCA4fko mice (sham vehicle, n¼ 5; TAC vehicle, n¼4; TAC ATA, n¼4). (k) The level of ANP and (l) BNP expression
were not signiﬁcantly different between TACþvehicle and TACþATA group (NS, not signiﬁcant). All error bars represent the s.e.m.
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PMCA4 regulates important signalling pathways in endothelial
cells (that is, the vascular endothelial growth factor-mediated
angiogenesis)38 and in smooth muscle cells (that is, the
neuronal nitric oxide synthase (nNOS)-mediated contraction)39.
Further studies are needed to fully characterize the role of
PMCA4 in endothelial cells and smooth muscle cells in the
regulation of cardiac hypertrophy.
Perhaps the most important aspect of this study is the possible
translational implications. We have demonstrated in this study
that interfering with the PMCA4-mediated signal using a
pharmacological inhibitor may be beneﬁcial for controlling
pathological hypertrophy. The nature of PMCA4 as a membrane
protein makes this molecule pharmacologically targetable. In
addition, ATPases are highly amenable to large-scale chemical
library screens. Using a medium-scale screening system we have
identiﬁed ATA as a potent PMCA4 inhibitor24. Strikingly,
inhibition of PMCA4 using ATA could suppress and reverse
cardiac hypertrophy. Observations using global and conditional
KO mouse models, as well as in vitro experiments by treating
isolated cardiomyocytes with ATA (1 mM), strongly support the
idea that ATA mainly works in cardiac ﬁbroblasts but not in
myocytes. Thus, this study provides direct evidence that cardiac
ﬁbroblasts can be targeted pharmacologically to treat myocardial
hypertrophy.
Whole-body phenotyping of our PMCA4 / mice, including
analyses of blood chemistry, nervous system, X-ray and dexascan
(see Supplementary Table 4) revealed no abnormalities,
indicating that targeting this molecule is unlikely to cause side
effects in any of these organ systems. However, our previous
observations showed that male PMCA4 / mice exhibited reduced
sperm motility20. Although the effect of systemic administration of a
PMCA4 inhibitor on fertility needs addressing, it should be noted
that there is a blood–testis barrier similar to the blood–brain barrier
that most small molecules do not cross40.
Although industrially reﬁned derivatives may be needed for
human drug development, ATA provides proof of principle for
our approach. Not only did it prevent pathological hypertrophy
when applied before overload but it also considerably reduced
hypertrophy when applied after the establishment of hypertro-
phy, which is a more realistic scenario for translating these results
to future clinical studies.
Methods
Animals. Mice with a targeted deletion of exon 2 and part of exon 3, which contain
the start codon of the Pmca4 gene were used in this study20. We used 8- to
10-week-old male PMCA4 KO mice for pressure-overload or exercise-induced
hypertrophy experiments. Age- and sex-matched WT littermates were used as
controls. For tissue-speciﬁc KOs, we generated the PMCA4ﬂox/ﬂox mice by ﬂanking
exon 2 and exon 3 of the Pmca4 gene with loxP sites (Supplementary Fig. 6). To
generate cardiomyocyte-speciﬁc KOs, we crossed these animals with aMHC-Cre
mice (obtained from Dr Michael Schneider’s laboratory41). To generate ﬁbroblast-
speciﬁc KO, we crossed PMCA4ﬂox/ﬂox mice with Postn-Cre mice (a generous gift
from Dr Simon Conway, Indiana University School of Medicine22). We used male,
8–10 weeks old C57Bl/6 mice, to test the effect of ATA during pressure overload
hypertrophy. Animal studies were performed in accordance with the United
Kingdom Animals (Scientiﬁc Procedures) Act 1986 and were approved by the
University of Manchester Ethics Committee.
Transverse aortic constriction. To produce a model of cardiac pressure overload,
mice were subjected to TAC or a sham operation. Mice were induced with 5%
isoﬂuorane, orally intubated and then placed on a ventilator set to 200 breaths per
minute, tidal volume 0.1ml (Minivent 845, Harvard Apparatus). Anaesthesia was
maintained at 3% isoﬂuorane in 100% O2 throughout the surgery. With the aid of a
binocular stereomicroscope (Olympus) the chest was opened via minithoracotomy,
to expose the aortic arch, and TAC was performed by tying a 7–0 silk suture
around a 27-gauge needle overlying the arch at the point between the brachioce-
phalic trunk and left common carotid artery. In our hands, this typically produces a
B25–30mmHg pressure gradient between the left and right carotid artery42,43.
For sham operations, the arch was exposed and a suture was passed around the
back of the aorta before removal without tying. The chest was then sutured and
0.1mg per kg body weight of buprenorphine was administered via i.p. injection.
Mice were recovered in a 30 C incubator before returning to normal housing.
Heart tissues were collected at the end of experiments, for histology and molecular
analyses.
For TAC experiments involving anti-sFRP2 antibody administration,
8-week-old PMCA4 /mice were injected i.p. with either 200mg per kg control
goat IgG or goat anti-mouse sFRP2 antibody (R&D Systems) 1 day before TAC.
They were then injected i.p. at this dose daily for a further 2 weeks (5 out of 7 days).
Echocardiography and haemodynamic analyses. For haemodynamic analysis,
mice were anaesthetised by i.p. injection of tribromoethanol (Avertin, 250mg per
kg body weight, Sigma). A midline cervical incision was made and the sternohyoid
muscles were retracted, to expose the right carotid artery, which was tied at the
bifurcation point, preventing regurgitation from the periphery. The right carotid
artery was occluded proximally, allowing an incision to be made with minimal
blood loss. A 1.4F pressure–volume catheter (SPR-839, Millar Instruments)
was inserted via the carotid artery and ascending aorta into the left ventricle.
Pressure–volume changes were recorded using a PowerLab system (Millar
Instruments) once traces had stabilized. Inotropic and lusitropic function were
assessed through analysis of the maximum and minimum rates of left ventricular
pressure change, dP/dtmax and dP/dtmin, respectively, using Millar’s PVAN software.
Transthoracic echocardiography was conducted to monitor the progression of
hypertrophy following TAC in the ATA treatment experiments under anaesthesia
with 1.5% isoﬂuorane. An Acuson Sequoia C256 ultrasound system ﬁtted with a
14-MHz transducer (Siemens) was used to image the heart in the two-dimensional
short-axis view, whereon M-mode echocardiography was recorded, to measure the
left ventricular end diastolic diameter (LVEDD), left ventricular end systolic
diameter, and diastolic posterior wall (dPW) and interventricular septal (dIVS)
thicknesses in diastole. Measurements were obtained using the leading-edge
method over a minimum period of three cardiac cycles, with the researcher blinded
to mouse genotype and treatment. Mean wall thickness was determined by
averaging the diastolic PW and IVS thicknesses, whereas LV mass was calculated
using the formula 1.055 [(LVEDDþ dPWþ dIVS)3 LVEDD3].
Exercise-induced hypertrophy. To produce a model of exercise-induced
hypertrophy, mice were swum twice a day for 90min, 5 out of 7 days for a period
of 4 weeks. An initial training period commenced exercise at 2 10min per day,
which was then increased in increments of 20min per day until the full 2 90min
per day was reached. Following each swim, mice were towel dried and then
maintained at 30 C until fully dry, with 4 h rest between sessions. Water was
maintained at a temperature of 30–32 C in 18-l tanks at a depth of 30 cm.
Sedentary controls were handled daily.
Isolation of adult and neonatal cardiomyocytes. Adult mouse cardiomyocytes
were isolated from 3- to 4-month-old animals. In brief, mice were killed by cervical
dislocation, the hearts were rapidly removed and then perfused via the aorta with
isolation solution pH 7.34 (134mM NaCl, 11mM glucose, 4mM KCl, 1.2mM
MgSO4, 1.2mM NaH2PO4 and 10mM HEPES) for 4min, followed by 9min
perfusion with a solution containing 0.6 and 0.075mgml 1 of collagenase type II
(Worthington) and proteases type XIV (Sigma-Aldrich), respectively. Hearts were
then perfused with Tyrode solution containing 50mM taurine pH 7.34 for 12min.
The ventricles were cut from the heart and placed in Tyrode-taurine solution. The
ventricles were then cut in half and pipetted up and down through a Pasteur
pipette in 5ml of Tyrode-taurine solution, to release the cardiomyocytes.
Adult rat cardiomyocytes were isolated and cultured following a protocol
described by O’Connell et al.44 Adult female Sprague–Dawley rats were
anaesthetized with 3% isoﬂurane and injected i.p. with 1,000 IU per kg body weight
heparin. Hearts were then excised, cannulated via the aorta and Langendorff
perfused with perfusion buffer (120.4mM NaCl, 5.5mM glucose, 14.7mM KCl,
1.2mM MgSO4-7H2O, 0.6mM Na2HPO4, 10mM Na-HEPES, 0.6mM KH2PO4,
4.6mM NaHCO3, 30mM Taurine and 10mM 2,3-butanedione monoxime (BDM))
for 4min at 4mlmin 1 at 37 C. The solution was then switched to digestion
buffer (perfusion buffer containing 2.4mgml 1 Type II Collagenase,
Worthington) for 3min, followed by digestion buffer containing 40 mM CaCl2 for a
further 8min after which hearts were cut below the atria and placed in a sterile
container ﬁlled with 5ml digestion buffer. Following transfer to a laminar ﬂow cell
culture hood, ventricles were cut into small pieces and 10ml myocyte stopping
buffer (perfusion buffer containing 10% fetal bovine serum (FBS) and 12.5 mM
CaCl2) added. The solution was pipetted up and down for 5min using a plastic
transfer pipette and placed in a 50-ml tube with an additional 5ml stopping buffer,
followed by centrifugation for 3min at 20 g and resuspension of the pellet in 20ml
stopping buffer containing 2mM ATP. Calcium was then reintroduced in three
stages by repeated centrifugation (20 g for 3min) and resuspension in 10ml
stopping buffer containing 100, 400 and 900 mM CaCl2. Following the ﬁnal
centrifugation, myocytes were resuspended in myocyte plating medium (Eagle’s
MEM w/ Hanks’ balanced salt solution (HBSS) containing 10% FBS, 10mM BDM,
100Uml 1 penicillin-G, 2mM Glutamine and 2mM ATP) pre-equilibrated in a
37 C 5% CO2 incubator and plated in 24-well plates on laminin-coated coverslips
for 1 h. Plating medium was then removed and myocytes gently washed with
pre-equilibrated myocyte culture medium (Eagle’s MEM w/HBSS containing
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1mgml 1 BSA, 10mM BDM, 100Uml 1 penicillin-G, 2mM glutamine,
5 mgml 1 insulin, 5 mgml 1 transferring, 5 ngml 1 selenium) and left for 24 h.
NRCMs were isolated from 1- to 3-day-old Sprague–Dawley rat neonates. Pups
were killed by cervical dislocation followed by decapitation, then brieﬂy rinsed in
70% ethanol for surface sterilization. Next, the hearts were collected into ﬁlter-
sterilized ADS solution pH 7.35 (116mM NaCl, 20mM HEPES, 1mM NaH2PO4,
5.5mM glucose, 5.5mM KCl and 1mM MgSO4) on ice. Following transfer to a
laminar ﬂow cell culture hood, ventricles were dissected from extraneous tissue and
atria, and cut into small pieces. Ventricular tissues were then digested through
shaking at 37 C in sterile ADS solution containing 0.6mgml 1 collagenase A
(Roche) and 0.6mgml 1 pancreatin (Sigma) for 7min. Cells were detached from
the tissue by passing several times through a pipette, collected from the supernatant
and discarded from this ﬁrst digestion. The digestion process was then repeated a
further seven times. Collected cells from digestions 2–8 were passed through a
70-mm cell strainer, to which 2ml of FBS (Invitrogen) was added to neutralize the
collagenase. The pooled cells were spun at 1,200 r.p.m. for 5min and the pellet
resuspended in 40ml of pre-plating medium (68% DMEM, 17% M199, 10% horse
serum, 5% FBS and 2.5 mgml 1 amphotericin B). Cardiac ﬁbroblasts were
removed from the cell suspension through plating in 10mm culture dishes for 1 h,
to allow them to adhere, and then retrieving the myocytes in the media for
counting. Cells were diluted to 1 106 cells per ml with plating medium (as for
pre-plating with the addition of 1 mM BRDU (5-bromo-2-deoxyuridine)) and
incubated for 24 h at 37 C following plating into 6-well BD Falcon Primaria tissue
culture plates (for expression analysis, 2.5 106 cells per well) or on laminin-
coated coverslips in 24-well plates (for immunostaining, 5 105 cells per well).
The following day, cardiomyocytes were washed twice with PBS and kept in
maintenance medium (80% DMEM and 20% Medium 199, 1% FBS, 2.5 mgml 1
amphotericin B and 1 mM BRDU) at 37 C.
Isolation of ACFs. ACFs were isolated from 3- to 4-month-old mice. Mice were
killed by cervical dislocation and their hearts were rapidly removed. The hearts
were then mashed with scalpels and digested with 10ml collagenase solution
(120mg collagenase A (Roche) and 12mg protease (Sigma) dissolved in 80ml PBS
solution) at 37 C for 5min, for three times. Cells were collected after each
digestion and the collagenase was deactivated by addition of FBS solution. The
harvested ﬁbroblasts were centrifuged for 5min at 220 g (Beckman Coulter Allegra
6R). The cell pellet was resuspended in 10ml ACF media (80% DMEM, 20% FBS,
1% penicillin/streptomycin, 1% Fungizone and 1% non-essential amino acids).
Fibroblasts were then plated in 10ml BD Primaria tissue culture plates overnight.
The next day, the media was removed and replaced with 10ml ACF media.
Cellular hypertrophy experiments. NRCM were cultured in cardiomyocyte
maintenance medium (68% DMEM, 17% M199, 10% horse serum, 5% FBS,
2.5 mgml 1 amphotericin B and 1 mM BrdU), whereas adult rat cardiomyocytes
were cultured in pre-equilibrated myocyte culture medium (Eagle’s MEM w/HBSS
containing; 1mgml 1 BSA, 10mM BDM, 100Uml 1 penicillin-G, 2mM
Glutamine, 5 mgml 1 insulin, 5 mgml 1 transferring and 5 ngml 1 selenium) for
24 h. Next, the medium was replaced with conditioned medium from ACFs culture.
To prepare the conditioned medium, ACFs isolated from WT or PMCA4 / mice
were plated in cardiomyocyte maintenance medium for 24 h. The media were
collected and used to culture NRCM. Cells were then stimulated with pheny-
lephrine (30 mM) for 72 h with or without 0.2 mgml 1 anti-sFRP2 antibody
(Abcam) for 72 h. To speciﬁcally visualize cardiomyocytes, cells were stained with
anti-a-actinin antibody (Sigma). The cell size was then measured using ImageJ
software (NIH). The level of sFRP2 in the conditioned medium of WT or
PMCA4 / ACFs was determined using ELISA (My BioSource) following the m
manufacturer’s protocol.
Intracellular calcium measurement. Intracellular calcium measurement was
carried out as described before24. Brieﬂy, 104 ACFs were plated in BD Primaria
96-well plates and incubated at 37 C for 24 h. The medium was replaced by 80 ml
of loading solution (5 mM Fluo-3 acetoxylmethylþ 0.1% Pluronic F.127 in HBSS
solution) and incubated at 37 C for 30min. Next, the medium was replaced by
100ml of fresh HBSS–BSA–probenecid solution (HBSS, 1% w/v BSA and 2.5mM
probenecid) and were incubated for 30min at 37 C. Cells were then washed
with 100 ml of HBSS–BSA–probenecid and ﬁnally maintained in 80 ml of fresh
HBSS–BSA–probenecid containing 1.26mM calcium chloride. Baseline
ﬂuorescence (F) was measured for 3min with ﬁlters for excitation at 485 nm and
for emission at 538 nm using a BMG FLUOstar Omega plate reader. Following
baseline ﬂuorescence measurement, 14 ml of Fmin solution (HBSS–BSA–probenecid
pH 7.45, 100 mM ionomycin, 10mM Thapsigargin and 20mM EGTA pH 8.0) was
added to each well, to deplete the calcium from the cells and leave only the
autoﬂuorescence, which was measured for 120min (Fmin). Finally, 16 ml of Fmax
(250mM calcium chloride in HBSS–BSA–probenecid) solution was added to
saturate the cells with calcium and ﬂuorescence was measured for another
5min (Fmax).
Western blotting and immunoﬂuorescence. Protein was extracted from
pelleted suspended or adherent cells through lysis in RIPA buffer (PBS
containing 1% IGEPAL CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 0.5mM
phenylmethylsulphonyl ﬂuoride, 500 ngml 1 Leupeptin, 1 mgml 1 Aprotinin and
2.5 mgml 1 Pepstatin A). Harvested tissue stored at  80 C since collection was
cut into small pieces and homogenized in RIPA buffer in a dounce homogenizer.
Cellular debris was removed from protein extracts by centrifugation (3,000 r.p.m.
for 5min at 4 C) and the supernatant stored at  80 C. Protein concentration
was determined using a bicinchoninic acid assay kit (Pierce) as per the
manufacturer’s instructions.
Western blot analysis was conducted using a standard protocol. Proteins were
separated by SDS–PAGE using 8% gels, transferred to Immobilon-polyvinylidene
diﬂuoride membrane (Millipore) and blocked in 4% BSA or 5% non-fat milk.
Primary antibodies used were: anti-PMCA4 (clone JA9) (Abcam; 1:1,000 for
western blotting, 1:100 for immunoﬂuoresence), anti-DDR2 (Abcam; 1:100),
anti-sFRP2 (Abcam; 1:1,000), anti-active b-Catenin (Millipore; 1:500), anti-
GAPDH (Abcam; 1:5,000) anti-b-actin (Abcam; 1:5,000) and anti-a-tubulin
(Abcam; 1:5,000). We used horseradish peroxidase-labelled secondary antibodies
(Cell Signaling; 1:5,000) and detected signal using enhanced chemiluminescence
(GE Healthcare) in a ChemiDoc XRSþ Imaging System (Biorad). Full blots of
cropped images are provided in Supplementary Fig. 14.
For immunoﬂuorescence, anti-a-actinin (Sigma; 1:100) and anti-phalloidin
(Molecular Probes; 1:100) antibody were used. We used Texas red or ﬂuorescein
isothiocyanate-labelled secondary antibodies (Jackson ImmunoResearch) for visual
detection.
Histology. Heart tissues were ﬁxed in 4% paraformaldehyde in PBS, embedded
in parafﬁn and sectioned at 5 mm thickness. Haematoxylin and eosin staining
and Masson’s trichrome stains were performed using standard procedures.
Cross-sectional cardiomyocyte size and percentage of interstitial ﬁbrosis were
assessed in haematoxylin and eosin-, and Masson’s trichrome-stained sections,
respectively, using ImageJ software.
RNA isolation and real-time RT–PCR. Total RNA was prepared from freshly
isolated heart tissues or cultured ACFs using Trizol reagent (Invitrogen) following
the manufacturer’s instructions. We used the QuantiTect-SYBR Green RT–PCR
system (Qiagen) for real-time qRT–PCR analysis. Data were calculated using the
DDCt method and are presented as fold induction of target gene transcripts relative
to control group. Reactions were performed in an ABI 7500 Fast System (Applied
Biosystems). The following primers were purchased from Qiagen (Quantitect
Primer Assay system): ANP, Mm_LOC230899_1_SG; BNP, Mm_Nppb_1_SG;
SFRP2 Mm_Sfrp2_1_SG; TCF4, Mm_Tcf4_va.1_SG; Pax2, Mm_Pax2_1_SG; and
GAPDH, Mm_Gapdh_2_SG. Threshold cycle (Ct) values were determined by
using the Sequence Detection System software. GAPDH levels were used as a
reference.
Microarray analysis. RNA was obtained and pooled from three batches of
ﬁbroblasts isolated either from PMCA4 / or WT mice. We used three
independent RNA pools of each genotype isolated with Trizol (Invitrogen)
following the manufacturer’s instructions. All the following steps were conducted
by the genomics and bioinformatics core facilities at the University of Manchester
following their standard protocols. Brieﬂy, we ﬁrst assessed the purity of
RNA using an Agilent Bioanalyzer 2100 (Agilent Technologies). Cochlear
complementary RNA (cRNA) was prepared by sequentially generating
complementary DNA with the one-Cycle cDNA Synthesis Kit and used for
hybridization to MOE430A Genechips (Affymetrix) and then cRNA was puriﬁed
and used as a template for the in vitro transcription reaction for cRNA ampliﬁ-
cation and biotin labelling. This was followed by hybridization to the GeneChip
arrays and scanned with a GeneChip Scanner 3000 7G–4C (Affymetrix). The
analysis was initially performed with MAS5.0 (Affymetrix) and Robust Multiarray
Average software45, which indicated high variability that was associated with the
biological variability and nonspeciﬁc hybridization. Further analysis was then
conducted using the software package PUMA (Propagating Uncertainty in
Microarray Analysis), to estimate the gene expression levels. To reduce the number
of false positives, the analysis of the fold change was used in combination with the
Probability of Positive Log Ratio (PPLR) algorithm from the PUMA package46.
Luciferase assay. The luciferase reporter for assessing b-catenin activity, which
contains TCF/LEF sites was a gift from Dr Randall Moon (Addgene plasmid
#12456)19. The reporter cassette containing NF-kB-binding sites was obtained
from Clontech. Constructs were cloned into the pAd-DEST Gateway vector
(Invitrogen), to produce adenoviruses expressing these reporter genes.
For luciferase assay, 7 105 NRCMs were plated in 24-well plates in 1ml
maintenance media for 24 h. Next, the media was changed with either maintenance
media or ﬁbroblasts conditioned media. Adenovirus-encoding the TCF/LEF-
luciferase construct was added and cells were then stimulated with 30 mM
phenylephrine for 72 h. Luciferase assays were performed using luciferase assay
reagent (Promega) following manufacturer’s recommended protocol.
The NF-kB-luciferase reporter was used to examine NF-kB activity in cardiac
ﬁbroblasts. In brief, 5 104 ACFs were plated in 24-well plates for 24 h. Next, the
cells were infected with the NF-kB reporter adenovirus and incubated for 72 h at
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37 C. Luciferase assays were performed using luciferase assay reagent (Promega)
following the manufacturer’s recommended protocol.
Whole-body phenotypic analysis. The study was performed on 12 male mice:
6 KOs and 6 control WTs. Phenotyping began when mice were 15 weeks of age.
Food consumption and body weight were monitored once a week between 16 and
21 weeks of age. Dysmorphology screen including body observation, physical
appearance and general behaviour was performed at 17 weeks of age. Blood
was collected by retro-orbital puncture after overnight fasting under isoﬂurane
anaesthesia at the age of 19 weeks for basic chemistry, blood lipid and haematology
analysis. At 20 weeks of age, indirect calorimetry was performed to evaluate energy
expenditure. At 21 weeks of age, blood was collected by retro-orbital puncture for
immunology (plasma IgG, IgA and IgM measurement) and enzymatic activities
analysis. Bone mineral density, body lean and fat content were evaluated by
Dexascan analysis at the age of 22 weeks. X-ray analysis was performed at the same
age. At 24 and 26 weeks of age, blood was collected by retro-orbital puncture for
metabolic and endocrine exploration. At the end of the study (30-week-old mice),
blood was collected by intra-cardiac puncture for coagulation tests.
Statistical analysis. Data are expressed as meanþ s.e.m. Student’s t-test or
one-way analysis of variance followed by post-hoc multiple comparison were used
where appropriate. The probability level for statistical signiﬁcance was set at
Po0.05.
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